BRIEF published on 03/27/2025 at 07:35, 1 year 7 months ago MaaT Pharma announces a capital increase of 13 million euros and 2024 annual results Financial Results Biotechnology Capital Increase MaaT013 AGvH
BRIEF published on 01/21/2025 at 18:05, 1 year 9 months ago Positive Results for MaaT033 Clinical Trial Biotechnology Security Oncology Clinical Trial MaaT033
PRESS RELEASE published on 12/10/2024 at 02:30, 1 year 10 months ago Inside Information / Other news releases
BRIEF published on 10/15/2024 at 07:35, 2 years ago MaaT Pharma Clinical Trial Recruitment Concluded Clinical Trial MaaT Pharma MaaT013 DSMB Notice AGvH Treatment
PRESS RELEASE published on 10/15/2024 at 07:30, 2 years ago Inside Information / Other news releases MaaT Pharma completes recruitment of its ARES Phase 3 Trial for MaaT013, a treatment for Acute Graft-versus-Host Disease, with topline results expected in January 2025 Clinical Trial MaaT Pharma MaaT013 ARES Phase 3 Trial Acute Graft-versus-Host Disease
BRIEF published on 09/04/2024 at 07:35, 2 years 2 months ago MaaT Pharma Announces Participation in Investor and Medical Conferences in September Investors Cancers Medical Conference MET Therapies Cell Transplantation
BRIEF published on 05/15/2024 at 07:35, 2 years 5 months ago MaaT Pharma successfully completes a fundraising of 19.2 million euros Biotechnology Fundraising Investment MaaT Pharma Clinical Tests
PRESS RELEASE published on 05/15/2024 at 07:30, 2 years 5 months ago Inside Information / News release on accounts, results MaaT Pharma announces successful completion of 19.2 million euros Global Offering with new shares, aims to fund R&D activities, Phase 3 trials, and broaden pipeline Biotechnology Fundraising Clinical Trials Global Offering MaaT Pharma
BRIEF published on 05/14/2024 at 19:39, 2 years 5 months ago MaaT Pharma Announces 18 Million Euro Global Offering and Strategic Developments Financial Strategy Phase 3 Trial Clinical-stage Biotechnology Global Offering Microbiome Ecosystem Therapies
PRESS RELEASE published on 05/14/2024 at 19:34, 2 years 5 months ago Inside Information / News release on accounts, results MaaT Pharma launches a global offering of approximately 18 million euros to fund R&D activities and expand shareholder base. Current shareholders commit to significant subscriptions Global Offering MaaT Pharma 18 Million Euros R&D Activities Shareholder Commitments
Published on 11/04/2026 at 00:05, 9 hours 50 minutes ago Scoping Study Begins for High-Grade Underground Mine Feed
Published on 11/04/2026 at 00:00, 9 hours 55 minutes ago RE Royalties Launches $5 Million Series 5 Green Bond Offering and Provides Strategic Growth Update
Published on 11/03/2026 at 23:30, 10 hours 25 minutes ago AT&T and Amdocs Expand Collaboration, Bringing Together Amdocs aOS and AT&T's AI-Enabled Framework to Simplify Operations and Improve Customer Experiences
Published on 11/03/2026 at 23:30, 10 hours 25 minutes ago GGL Resources Corp. Issues Post-Consolidation Shares to Strategic Metals Ltd.
Published on 11/04/2026 at 09:15, 40 minutes ago Fox ESS Signs Youngest Porsche Carrera Cup Germany Winner, Champion On and Off the Track
Published on 11/04/2026 at 09:15, 40 minutes ago Omnissa expands Sovereign Solution to more markets, designed to give enterprises a safe place to run AI
Published on 11/04/2026 at 09:05, 50 minutes ago New global Mouth-to-Body Health Institute aims to turn oral-systemic science into better prevention and care
Published on 11/04/2026 at 09:00, 55 minutes ago Original-Research: GFT Technologies SE (von NuWays AG): BUY
Published on 11/04/2026 at 09:00, 55 minutes ago Original-Research: CEOTRONICS AG (von NuWays AG): BUY
Published on 11/03/2026 at 18:00, 15 hours 55 minutes ago Outstanding Shares and Voting Rights Monthly Statement - 31 October 2026
Published on 11/03/2026 at 17:45, 16 hours 10 minutes ago Declaration of voting rights at the end of October 2026
Published on 11/02/2026 at 18:30, 1 day 15 hours ago Disclosure of transactions in own shares from October 26 to October 30, 2026
